LifeMap Sciences, Inc., a life sciences technology company and a subsidiary of BioTime, Inc., has released the GeneAnalytics v1.1, a powerful and easy-to-use gene set analysis tool that rapidly contextualizes RNAseq and microarray-derived gene expression patterns and function signatures.

The tool leverages LifeMap Sciences’ comprehensive integrated biomedical knowledgebase, comprised of GeneCards, MalaCards, and LifeMap Discovery, to help researchers identify diseases, biological pathways, and tissues and cell types associated with gene sets derived from next generation sequencing (NGS) or microarray analysis experiments.



“The new GeneAnalytics version includes significant enhancements targeted at the NGS analysis market,” said Yaron Guan-Golan, chief marketing officer at LifeMap Sciences. “Our unique technology makes GeneAnalytics a powerful and easy-to-use solution for academic researchers, service providers, biopharma, and diagnostic companies.”



GeneAnalytics v1.1 features enhanced capabilities for identifying diseases and biological pathways that may be associated with genes identified by NGS experiments. A key feature included in the updated version is the presentation of known disease causative mutations, which assist users during gene variant prioritization by identifying variants that may be linked to diseases of interest.



GeneAnalytics is part of LifeMap’s GeneCards Suite Premium Tools, which also includes VarElect, a NGS Phenotyper that swiftly prioritizes gene variants according to their associations to a disease or phenotype of interest, and GeneALaCart, the GeneCards batch querying application. These enable researchers to rapidly and cost-effectively analyze data derived from NGS of whole genomes, exomes, and transcriptomes, and to identify gene variants and aberrant gene functions for basic, clinical, and applied biomedical research and discovery.



The GeneCards Suite Premium Tools, launched in 2014, employ LifeMap’s integrated biomedical knowledgebase, which includes GeneCards, the leading human gene database; MalaCards, the human disease database; and LifeMap Discovery®, the cells and tissues database. LifeMap holds the exclusive worldwide license to market GeneCards, MalaCards, GeneAnalytics, VarElect and GeneAlaCart from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science.



LifeMap Sciences is a life sciences technology company that offers integrated, streamlined solutions that empower life scientists worldwide to conduct cutting edge basic, clinical, and applied biomedical research.